Khindri Sanjeev sold $85K of LQDA

Khindri Sanjeev (Chief Development Officer) sold 1,185 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Khindri Sanjeev
Published Jul 15, 2026, 12:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosed transaction is an open-market sale of 1,185 shares at about $71.51 weighted average, executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may treat this as routine insider selling with limited incremental information, but it can be used to monitor insider behavior trends.

03

What to watch

The article does not state whether additional sales/purchases occurred around the same period beyond the two trades listed, nor does it provide context on total compensation or prior sale cadence.

Relevance 2/10Novelty 4/10Timing: SEC Form 4 filed 2026-07-14, covering a sale executed 2026-07-13.

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by an officer (Chief Development Officer).

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia insider Khindri Sanjeev, Chief Development Officer, sold $84,740 of LQDA shares via a Rule 10b5-1 plan on 2026-07-13.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely short-lived.

Evidence & confidence

The filing is a disclosed open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no accompanying fundamental catalyst (earnings, guidance, trial, deal, or regulatory action).

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even planned 10b5-1 sales can coincide with internal views on timing or liquidity needs, so traders may still watch for follow-on insider activity or changes in guidance.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure.

  • Khindri Sanjeev

    Chief Development Officer who sold shares.

  • Rule 10b5-1 plan

    Pre-arranged plan cited as Yes, indicating the sale was scheduled in advance.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.